← CorMedix Inc. (CRMD) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
CorMedix Inc. (CRMD)
Pharmaceutical Preparations · market cap $605M · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
CorMedix Inc. (CRMD) is a specialty pharmaceutical company with a market cap of ~$610M focused on anti-infective catheter lock solutions and a small pipeline of complementary assets. Its lead product, a taurolidine and heparin catheter lock solution (also marketed as Neutrolin), has achieved commercial-stage revenues — $312M in fiscal 2025 versus near-zero prior years — suggesting a recently launched or ramping approved product, alongside ongoing Phase 3 work in CLABSI and chronic kidney failure. The company carries $178M in net cash with no debt, and 19% of the float is sold short.
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| CRMD-001-Deferiprone | Phase 2 | Contrast-Induced Acute Kidney Injury |
| (taurolidine and heparin) catheter lock solution | Phase 3 | Central Line Associated Blood Stream Infections (CLABSI) |
| Neutrolin | Phase 3 | Kidney Failure, Chronic |
Price & technical context
3-month
-15.2%
6-month
+5.7%
12-month
-36.2%
52-wk range
$6.25–$12.73
vs 50-day MA
-5.8%
vs 200-day MA
-7.5%
Realized vol
64.8%
Max drawdown
-62.3%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CRMD (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.